医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Axial Biotherapeutics to Present at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders’ Emerging Management Therapies for Childhood Neurodevelopmental Disorders Scientific Symposium

2020年02月05日 PM10:01
このエントリーをはてなブックマークに追加


 

WALTHAM, Mass.

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that Stewart Campbell, Ph.D., Senior Vice President, Research & Development, will present a translational overview of Axial’s Autism program at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders’ (CCTRND) Emerging Management Therapies for Childhood Neurodevelopment Disorders Inaugural Scientific Symposium on Thursday, February 6, 2020 at 11:00 AM AEST (Wednesday, February 5, 2020, 7:00 PM ET) at the Queensland Children’s Hospital in South Brisbane, Queensland, Australia.

About Axial Biotherapeutics

Axial Biotherapeutics is a clinical stage biotechnology company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of central nervous system (CNS) and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease and Autism Spectrum Disorder.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005198/en/

CONTACT

Investor Contact:

Julie Seidel

Stern Investor Relations, Inc.

212-362-1200

julie.seidel@sternir.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • TIENS Group will Become a Global Participant in the Future Massive Health Industry
  • エンヨ・ファーマがB型慢性肝炎患者でVonafexor(EYP001)を検討中の第2a相試験2件から得た16週目のトップライン中間解析結果を発表
  • Dr. Reddy’s Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve® in the U.S. Market
  • WNS Launches PRECIZON to Deliver Cloud-based Competitive Intelligence for Life Sciences Industry
  • Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study